Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer
出版年份 2023 全文链接
标题
Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer
作者
关键词
-
出版物
JAMA Oncology
Volume -, Issue -, Pages -
出版商
American Medical Association (AMA)
发表日期
2023-10-26
DOI
10.1001/jamaoncol.2023.4255
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
- (2022) Robert J. Motzer et al. Journal of the National Comprehensive Cancer Network
- 2-weekly versus 3-weekly docetaxel for metastatic castration-resistant prostate cancer: complete quality of life results from the randomised, phase-III PROSTY trial
- (2022) Miikka Lehtonen et al. ACTA ONCOLOGICA
- Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
- (2021) Oliver Sartor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study
- (2021) Cora N. Sternberg et al. EUROPEAN UROLOGY
- EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer
- (2020) Philip Cornford et al. EUROPEAN UROLOGY
- Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel – A Final Analysis of the Prosty II Trial
- (2020) PIRKKO-LIISA KELLOKUMPU-LEHTINEN et al. ANTICANCER RESEARCH
- Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients
- (2019) H.J. Boyle et al. EUROPEAN JOURNAL OF CANCER
- Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
- (2019) Ronald de Wit et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database
- (2019) Nicolas Delanoy et al. EUROPEAN JOURNAL OF CANCER
- Unknown
- (2018) BJU INTERNATIONAL
- Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting
- (2018) William K. Oh et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer—PROSELICA
- (2017) Mario Eisenberger et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial—FIRSTANA
- (2017) Stéphane Oudard et al. JOURNAL OF CLINICAL ONCOLOGY
- Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial
- (2017) Tomasz M Beer et al. LANCET ONCOLOGY
- Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial
- (2016) Alexander Meisel et al. EUROPEAN JOURNAL OF CANCER
- First-line treatment in senior adults with metastatic castration-resistant prostate cancer: A prospective international registry
- (2016) Jean-Pierre Droz et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer
- (2015) R.J. van Soest et al. EUROPEAN JOURNAL OF CANCER
- Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer
- (2015) Robert J. van Soest et al. EUROPEAN UROLOGY
- Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies
- (2015) Nader Al Nakouzi et al. EUROPEAN UROLOGY
- Biweekly cabazitaxel as post-docetaxel treatment for metastatic castration resistant prostate cancer (mCRPC): Findings from an early safety analysis of the Prosty II trial.
- (2015) Pirkko-Liisa Irmeli Kellokumpu-Lehtinen et al. JOURNAL OF CLINICAL ONCOLOGY
- Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results
- (2015) Michael J. Morris et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: Results of the European compassionate-use programme
- (2014) Axel Heidenreich et al. EUROPEAN JOURNAL OF CANCER
- Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology
- (2014) Jean-Pierre Droz et al. LANCET ONCOLOGY
- Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial
- (2014) Anne M. Horgan et al. Journal of Geriatric Oncology
- World Medical Association Declaration of Helsinki
- (2013) JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial
- (2013) Pirkko-Liisa Kellokumpu-Lehtinen et al. LANCET ONCOLOGY
- Screening older cancer patients: first evaluation of the G-8 geriatric screening tool
- (2012) C. A. Bellera et al. ANNALS OF ONCOLOGY
- TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer
- (2011) Stephane Oudard Future Oncology
- 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
- (2010) M.S. Aapro et al. EUROPEAN JOURNAL OF CANCER
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Identifying Patients at High Risk for Neutropenic Complications During Chemotherapy for Metastatic Breast Cancer With Doxorubicin or Pegylated Liposomal Doxorubicin
- (2009) George Dranitsaris et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
- (2008) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started